Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | MEP1B | Q16820 | 3/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179162 | 0.89 | FOLH1 (0.54) | FOLH1ANPEPENPEPSLC7A5 | |
| SCHEMBL21577910 | 0.87 | FOLH1 (0.46) | FOLH1ANPEPENPEPSLC7A5MEP1B | |
| SCHEMBL20179209 | 0.87 | FOLH1 (0.42) | FOLH1ANPEPENPEPF10SLC7A5 | |
| SCHEMBL21577917 | 0.86 | SLC7A5 (0.53) | FOLH1SLC7A5 | |
| SCHEMBL21578003 | 0.86 | FOLH1 (0.48) | FOLH1ANPEPENPEPF10SLC7A5 | |
| SCHEMBL21577993 | 0.86 | FOLH1 (0.46) | FOLH1ANPEPENPEPSLC7A5MEP1B | |
| SCHEMBL21577919 | 0.85 | FOLH1 (0.45) | FOLH1ANPEPENPEPF10SLC7A5 | |
| SCHEMBL26039018 | 0.85 | FOLH1 (0.40) | FOLH1ANPEPENPEPF10SLC7A5 | |
| SCHEMBL21577920 | 0.84 | FOLH1 (0.47) | FOLH1ANPEPENPEPSLC7A5MEP1B | |
| SCHEMBL21577908 | 0.84 | FOLH1 (0.44) | FOLH1ANPEPENPEPSLC7A5MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2021-11-18 | — | — | US | disclosed |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | GPI, TPI1, HPGDS | FOLH1 10/4885ANPEP 1023/4885ENPEP 114/4885 |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | TPI1, HPGDS, GPI | FOLH1 39/4885ANPEP 1063/4885ENPEP 117/4885 |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | GLS, HPGDS, GPI | FOLH1 15/4885ANPEP 1140/4885ENPEP 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.